2
Announcements
Trials
Browse
Landscape
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Observational
1
Sponsor
Cancer Type
Lymphoid
1
Conditions
Neoplasms
7
Brain Neoplasms
4
Pain
2
Neuralgia
2
Glioma
2
Depression
2
Visceral Pain
1
Recurrence
1
Rectal Neoplasms
1
Pituitary Neoplasms
1
Pancreatic Neoplasms
1
Neurologic Manifestations
1
Lymphoma, Follicular
1
Language Disorders
1
Headache
1
Glioblastoma
1
Fatigue
1
Depressive Disorder, Major
1
Cognitive Dysfunction
1
Carcinoma, Renal Cell
1
Cancer Survivor
1
Anxiety Disorders
1
Agnosia
1
Acromegaly
1
Interventions
Rituximab
301
Cyclophosphamide
241
Peripheral Blood Stem Cell Transplantation
115
fludarabine phosphate
111
Filgrastim
93
Etoposide
85
Radiotherapy
81
Lenalidomide
81
Vincristine
79
Prednisone
79
Mycophenolic Acid
67
Doxorubicin
62
Whole-Body Irradiation
59
Cyclosporine
59
Bendamustine Hydrochloride
59
Melphalan
57
Tacrolimus
54
Busulfan
52
obinutuzumab
50
fludarabine
50
Cytarabine
49
Methotrexate
45
Antilymphocyte Serum
43
Bortezomib
42
Methylprednisolone
37
Carmustine
37
sargramostim
36
ibritumomab tiuxetan
33
ibrutinib
30
Dexamethasone
30
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Lymphoma, Follicular
×
Transcranial Magnetic Stimulation
×
Clear all
NCT01718730
2019-10-22
Cortical Excitability and Inhibition in MDD
Mayo Clinic
Completed
23 enrolled